First month results in clinical trials showed an average weight loss of approximately 3.8 percent of baseline body weight at the 2.4 mg dose, but most researchers are still at 0.25 mg during this period
Not for human consumption, nor medical, veterinary, or household uses
Unfortunately, there are no studies exploring why this relationship might exist

Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with comorbidities The medication slows gastric emptying and may cause gastrointestinal side effects including nausea and abdominal discomfort, which could indirectly affect sleep quality Weight loss achieved through Wegovy may improve obesity-related sleep disorders such as obstructive sleep apnoea Practical strategies include eating final meals 34 hours before bedtime, maintaining consistent sleep schedules, and managing gastrointestinal side effects Seek medical advice if sleep disturbances persist beyond 23 weeks, cause excessive daytime sleepiness, or are accompanied by severe symptoms Table of Contents Understanding Wegovy and Its Effects on Sleep Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

K2 = limited community
While Ozempic isnt directly linked to hair loss in its list of common side effects, some users have reported experiencing hair thinning or loss